Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Cyclacel and Xcyte in reverse merger

Executive Summary

Cancer company Cyclacel will reverse merge with immune system therapeutics firm Xcyte to form Cyclacel Pharmaceuticals Inc., a public company that will have clinical- and preclinical-stage cancer candidates.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Reverse Acquisition
    • Payment Includes Stock
    • Includes Contract
    • Full Acquisition
    • Intra-Biotech Deal

Related Companies

UsernamePublicRestriction

Register